FDA approves rechargeable DBS device for patients with movement disorders

The FDA has approved a rechargeable deep brain stimulation device with remote programming for individuals living with movement disorders, according to the manufacturer.

According to a release from Abbott, the Liberta RC DBS system is roughly one-third smaller than implantable and rechargeable DBS devices currently commercially available in the United States, and only needs to be recharged about every 5 weeks, or approximately 10 times per year, via a wireless charger.

The wireless system allows individuals to remain active while wearing it, the company said in the release.

“In developing the Liberta RC DBS system, our focus has been on the unique experiences of individuals with chronic conditions like movement disorders,” Pedro Malha, vice president of neuromodulation at Abbott, said in the release. “ This system exemplifies our drive to provide patient-first solutions, combining effective therapy, effortless recharging and remote programming capabilities.”